Compare Iron Mountain Inc (IRM) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iron Mountain Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Iron Mountain Inc trades at $114.51 (market cap $34.46B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Iron Mountain Inc is far larger — about 3.4× State Street SPDR S&P Biotech ETF's market cap, and Iron Mountain Inc pays a 2.99% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iron Mountain Inc for 80 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| IRM | XBI | |
|---|---|---|
Market Cap | $34.46B | $10.11B |
Volume | 1,379,608 | 12,903,266 |
Sector | Real Estate | Broad Market / Factor |
52-Week High | $133.06 | $169.55 |
52-Week Low | $78.86 | $104.99 |
Typical Hold Time | 80 Days | 38 Days |
Enterprise Value | $53.87B | — |
Dividend Yield | 2.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Iron Mountain (IRM) trades at $112.97, down 2.38% with a bearish technical signal. The company shows strong revenue growth from $6.9B in 2025 to $7.6B projected for 2026, though net margins remain thin at 2.09%. Recent earnings beats and a 300MW data center pipeline expansion highlight growth initiatives. Analyst consensus is bullish with a $142.75 price target, representing 26% upside potential from current levels.
IRM offers compelling growth in data center and digital services but carries significant debt risk with 79.04% debt-to-asset ratio. The stock presents opportunity for investors seeking exposure to digital infrastructure expansion, though high leverage and thin margins require careful monitoring. Current technical weakness may provide entry points for long-term investors aligned with analyst optimism.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite an oversold RSI reading. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive news flow around biotech catalysts. Recent articles highlight XBI's biotech focus versus broader healthcare ETFs, with expense ratio comparisons and volatility considerations.
The outlook remains cautious due to technical weakness and high volatility, though sector-specific catalysts like cancer vaccine developments and M&A activity provide potential upside. Key risks include sector volatility, regulatory uncertainty, and competitive ETF offerings with lower fees.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Iron Mountain Inc
Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
